How does targeted therapy differ from chemotherapy, and are the side effects the same?

Chemotherapy damages rapidly dividing cells — both cancer and some normal cells — so hair loss, nausea, and low immunity are common. Targeted drugs bind specific targets on cancer cells (e.g. EGFR, HER2, ALK). Side effects are often class-specific, such as rash, diarrhea, or high blood pressure, and are not identical to chemo.

Why must genes or biomarkers be tested before starting targeted therapy?

Targeted therapy is like a key for a specific lock — without the mutation or protein the drug binds, it will not work. Tissue biopsy or next-generation sequencing (NGS) helps select the right drug, avoid unnecessary treatment, and supports reimbursement under medical indications.

Is targeted therapy expensive, and can Thai universal coverage, social security, or civil servant schemes pay?

Out-of-pocket, costs often run tens of thousands to hundreds of thousands of baht per month depending on the drug. Thailand's main health schemes now include many targeted agents on the national essential medicines list; when test results and indications meet criteria, patients can usually claim benefits without paying full price.

When are PARP inhibitors used in cancer treatment?

PARP inhibitors such as olaparib are often used in cancers with BRCA1/BRCA2 mutations or homologous recombination deficiency — as maintenance after chemo in ovarian cancer and as adjuvant/maintenance in some breast cancers, per the oncology team's plan.

Category: Medical Oncology & Targeted Therapy

Targeted Therapy: Replace, Combine, or After Chemo? Treatment Protocols and Coverage Explained

Q: Can targeted therapy replace, combine with, or follow chemotherapy?

All three patterns are possible, depending on cancer type, stage, and biomarker results — combined with chemo (concurrent) in HER2-positive breast cancer or some colorectal cancers; replacing chemo as first-line when EGFR or ALK is present in lung cancer; or after chemo as maintenance/adjuvant, e.g. PARP inhibitors in BRCA-mutated ovarian or breast cancer.

Q: Can EGFR-TKIs truly replace chemotherapy in lung cancer?

In NSCLC with an EGFR mutation, first-line EGFR-TKIs such as osimertinib or erlotinib often improve symptoms with fewer side effects than chemo in suitable patients — but gene testing must confirm eligibility first.

By Asst. Prof. Dr. Norawit Raatpiboon · Last updated: August 2026

Quick Answer (BLUF)

Targeted therapy can be used together with chemotherapy, instead of chemotherapy, or after chemotherapy — all three patterns are valid depending on cancer type, stage, and genetic biomarker results. Although targeted drugs are costly out-of-pocket, Thailand’s main health schemes (Universal Coverage, Social Security, Civil Servant Medical Benefit) list many agents and cover them when test results and indications meet criteria.

Emergency symptoms during targeted therapy or chemotherapy — seek care immediately

Fever > 38°C (100.4°F) or chills with severe fatigue (infection risk during chemo)
Shortness of breath, chest pain, or new coughing up blood
Severe rash, peeling, or blistering with fever (risk of Stevens-Johnson / DRESS from some targeted drugs)
Severe diarrhea, persistent vomiting, or confusion from dehydration
Abnormal bleeding, blood in urine, or easy bruising

This list is not exhaustive — if unsure, contact your oncology team or treating hospital immediately.

1. Three clinical patterns for using targeted therapy

The question “Do I take or inject this after chemo, or use it instead?” has no single answer — oncologists choose based on targeted therapy guidelines aligned with tumor type, stage, and gene test results.

1.1 Combined with chemotherapy (Concurrent / Combination)

Pattern: Targeted therapy and chemotherapy sit in the same plan (or alternate within the same course) to boost effectiveness.

Clinical examples: HER2-positive breast cancer often uses a monoclonal antibody against HER2 (e.g. trastuzumab ± pertuzumab) with chemotherapy; some colorectal cancers use an anti-EGFR monoclonal antibody (e.g. cetuximab) with chemotherapy when RAS is wild-type.

1.2 Replacing chemotherapy (Monotherapy / First-line)

Pattern: Targeted therapy is the main drug — often oral tablets or injections depending on the agent — without starting with chemotherapy first.

Clinical examples: Non-small cell lung cancer (NSCLC) with an EGFR mutation often uses an EGFR-TKI (e.g. osimertinib, erlotinib) as first-line; with an ALK rearrangement, an ALK inhibitor (e.g. alectinib, crizotinib) is used.

1.3 After chemotherapy (Maintenance / Adjuvant)

Pattern: After surgery or completing a chemo course, targeted therapy continues to reduce recurrence risk.

Clinical examples: Cancers with BRCA1/BRCA2 mutations may use a PARP inhibitor (e.g. olaparib) as maintenance in ovarian cancer or adjuvant therapy in some breast cancers, per the treating team’s plan.

Comparison table: three usage patterns

Targeted therapy usage patterns — responsive card-stack at ≤720px
Pattern	Medical description	Example cancer / biomarker	Treatment goal
Concurrent	Targeted therapy + chemotherapy in one plan	HER2+ breast cancer · RAS wild-type colorectal cancer	Boost tumor cell kill / faster disease control
First-line / Monotherapy	Targeted therapy as primary drug — no chemo to start	NSCLC + EGFR · NSCLC + ALK	Control disease with fewer side effects than chemo in suitable patients
Maintenance / Adjuvant	Given after surgery or finishing chemotherapy	BRCA-mutated · ovarian / breast cancer	Reduce recurrence · long-term disease control

Plan your health care during treatment

Analyze severity and receive personalized guidance from our Advisory team.

Take the free cancer-care urgency assessment

2. How targeted therapy differs from chemotherapy

Chemotherapy usually acts on rapidly dividing cells — both cancer and some normal cells (hair follicles, gut lining, blood cells) — causing hair loss, nausea, and infection risk when white blood cells drop.

Targeted therapy is designed to bind specific targets on cancer cells (e.g. EGFR, HER2, ALK, VEGF, PARP). Side effects are often class-specific, such as rash, diarrhea, protein in urine, or high blood pressure — not identical to chemo, but still require close monitoring.

Treatment comparison table

Chemotherapy vs targeted therapy — treatment dimensions
Dimension	Chemotherapy	Targeted therapy	Patient notes
Mechanism	Damages rapidly dividing cells	Binds specific targets on cancer cells	Targeted drugs require a matching biomarker
Route of administration	Intravenous infusion / oral (per regimen)	Oral tablets / injection (per agent)	Not every cancer has an oral alternative to chemo
Common side effects	Hair loss, nausea, low blood counts	Rash, diarrhea, high blood pressure (varies by drug)	Report new symptoms promptly
Pre-treatment testing	Performance status / kidney / liver assessment	Mandatory gene / protein biomarker testing	Tissue biopsy or NGS as ordered
Cost (out-of-pocket)	Thousands to tens of thousands of baht per cycle	Tens of thousands to hundreds of thousands of baht per month	Main health schemes may cover when indications are met

3. Why must biomarkers be tested before targeted therapy?

Targeted therapy works like a “key for a specific lock” — if cancer cells lack the target the drug binds, the treatment will not help and may waste valuable time.

Step 1: Send tissue or fluid (e.g. pleural fluid) for immunohistochemistry (IHC) or next-generation sequencing (NGS)

Step 2: Identify biomarkers — e.g. EGFR, ALK, ROS1, HER2, BRCA, KRAS/NRAS

Step 3: Select targeted therapy and concurrent or maintenance plan per oncology guidelines

Step 4: Use test results to support reimbursement under health-scheme criteria

4. Cost and treatment coverage (Universal Coverage / Social Security / Civil Servant)

4.1 Out-of-pocket payment

Many targeted agents are expensive — typically tens of thousands to hundreds of thousands of baht per month, depending on drug, dose, and duration. Plan with your oncology team and the hospital’s benefits office.

4.2 Thailand’s main health schemes

Universal Coverage (UC / “Gold Card”) · Social Security (SSO) · Civil Servant Medical Benefit Scheme (CSMBS)
Many targeted drugs are on the national essential medicines list (List J(2) and related lists). When test results and indications meet criteria, patients can usually claim benefits without paying full price.
Typical pathway: physician orders biomarker testing → indication confirmed → hospital submits claim per scheme (details vary by hospital and drug).

Latest coverage details: check with NHSO (National Health Security Office) and your hospital’s benefits staff — drug lists are updated periodically.

Scientific mechanism (summary by the author)

Cancer cells often carry mutations that keep signalling pathways active continuously (“oncogenic addiction”) — targeted drugs block these pathways. For example, EGFR-TKIs inhibit growth signals in lung cells; anti-HER2 antibodies help the immune system recognize and destroy HER2+ cells; PARP inhibitors exploit cells that cannot repair DNA (synthetic lethality in BRCA-deficient cells).

Chemotherapy uses cytotoxic agents to block cell division at various cell-cycle stages — broad effectiveness but lower selectivity. Choosing concurrent vs sequential therapy relies on RCT data and biomarkers from PubMed/NCI.

Mechanism summary by Asst. Prof. Dr. Norawit Raatpiboon — not a substitute for oncology consultation.

Frequently asked questions (FAQ)

Can targeted therapy replace, combine with, or follow chemotherapy?

All three are possible — concurrent in HER2+ or some colorectal cancers, first-line monotherapy in EGFR/ALK lung cancer, maintenance after chemo in BRCA-mutated ovarian or breast cancer.

Are targeted therapy side effects the same as chemotherapy?

No — chemo often causes hair loss and low blood counts; targeted drugs more often cause rash, diarrhea, or high blood pressure, depending on the agent.

Must genes be tested before starting targeted therapy?

Yes — nearly all cases require biomarker confirmation from tissue or NGS first, so the drug works and reimbursement criteria can be met.

Does Universal Coverage pay for targeted therapy?

Many agents are covered when test results and indications meet essential-medicines criteria — consult your physician and hospital benefits staff.

When are PARP inhibitors used?

Usually in cancers with BRCA mutations or homologous recombination deficiency (HRD) — as maintenance after chemo or adjuvant therapy per the oncology team’s plan.

Can EGFR-TKIs truly replace chemotherapy in lung cancer?

In NSCLC with an EGFR mutation, first-line EGFR-TKIs are often the primary choice — but gene testing must confirm eligibility first.

Academic references (E-E-A-T)

Prepared by: Asst. Prof. Dr. Norawit Raatpiboon

Medical disclaimer

This article provides general education on medical oncology and targeted therapy. It is not individualized medical advice. Choosing concurrent, monotherapy, or maintenance regimens must follow the judgment of your medical oncologist and multidisciplinary team. For emergencies, contact a hospital immediately.